echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Notice on Publicly Soliciting Opinions on "Chimeric Antigen Receptor T Cell (CAR-T) Product Application and Marketing Clinical Risk Management Plan Technical Guidelines (Draft for Solicitation of Comments)"

    Notice on Publicly Soliciting Opinions on "Chimeric Antigen Receptor T Cell (CAR-T) Product Application and Marketing Clinical Risk Management Plan Technical Guidelines (Draft for Solicitation of Comments)"

    • Last Update: 2021-10-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Chimeric antigen receptor T cell therapy products have the characteristics of novelty, complexity and technical specificity.
    With the development of such products and the successive application for listing, it will promote the early detection of the risks of such products and provide effective risks.
    Minimal measures to ensure that the safety risk is controllable after listing, and it is necessary to put forward requirements and provide guidance on the clinical risk management plan for applying for listing

    .
    Our center drafted the "Technical Guidelines for the Clinical Risk Management Plan for the Application and Marketing of Chimeric Antigen Receptor T Cells (CAR-T) Products (Draft for Comment)" on the basis of full investigation

    .

    We sincerely welcome valuable comments and suggestions from all walks of life on the solicitation draft, and timely feedback to us for follow-up improvement
    .
    The time limit for soliciting opinions is 1 month from the date of publication

    .

    Please send your feedback to the mailbox of the following contact:

    Contact: Huang Yunhong, Zhao Chenyang

    Contact: huangyh@cde.
    org.
    cn, zhaocy@cde.
    org.
    cn

    Thank you for your participation and great support

    Drug Evaluation Center of the State Drug Administration

    September 18, 2021

    Relevant attachments

    1 Draft of Technical Guidelines for Clinical Risk Management Plan for Application of Chimeric Antigen Receptor T Cell (CAR-T) Cell Therapy Products.
    pdf
    2 Drafting instructions.
    pdf
    3 Feedback form for soliciting opinions.
    docx
    1 chimeric T cell antigen receptor (CAR-T) cell therapy products listed declaration clinical risk management plan draft technical guidelines .
    pdf
    2 drafting notes .
    pdf
    3 solicit feedback form .
    docx
    a chimeric antigen receptor T cells (CAR-T) Cell Therapy Product Application and Marketing Clinical Risk Management Plan Technical Guiding Principles Draft.
    pdf
    1 Chimeric Antigen Receptor T Cell (CAR-T) Cell Therapy Product Application and Marketing Clinical Risk Management Plan Technical Guiding Principles Draft for Comment .
    pdf
    chimeric T cell antigen receptor (CAR-T) cell therapy products listed declaration clinical risk management plan draft technical guidelines .
    pdf
    2 drafting notes .
    pdf
    2 drafting notes .
    pdf
    drafting instructions .
    pdf
    3 comments feedback Form .
    docx
    3 Feedback form for soliciting opinions.
    docx
    Feedback form
    for soliciting opinions.
    docx
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.